3-甲氧基-6-哌嗪-1-基哒嗪 | 83774-21-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 3-甲氧基-6-哌嗪-1-基哒嗪
• 英文名称: 3-methoxy-6-(1-piperazinyl)pyridazine
• 英文别名: 4-(6-Methoxypyridazin-3-yl)piperazine；3-methoxy-6-piperazin-1-yl-pyridazine；1-<6-Methoxy-pyridazinyl-(3)>-piperazin；1-<6-Methoxypyridazinyl-(3)>-piperazin；3-Methoxy-6-piperazin-1-ylpyridazine
• CAS: 83774-21-4
• 化学式: C₉H₁₄N₄O
• mdl: MFCD16652884
• 分子量: 194.236
• InChiKey: UHUQMOCHDLJAKS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.555
• 拓扑面积：
  50.3
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  3-甲氧基-6-哌嗪-1-基哒嗪 以 氢溴酸 、 异丙醇 为溶剂， 生成 4-(6-hydroxypyridazin-3-yl)piperazine hydrobromide
  参考文献：
  名称：

  4-Amino-6,7-dimethoxy-2-(4-heteroaryl-piperazino)quinazoline

  摘要：

  公式为##STR1##的2,4-二氨基喹唑啉化合物或其药学上可接受的盐，其中R是通过其一个碳原子与哌嗪环相连的嘧啶基、吡嗪基、吡啶啉基或三嗪基，可选择地被羟基、卤素、烷基、芳基烷基、烷氧基、芳基烷氧基、烷硫基、芳基、芳基氧基和某些氨基取代；它们作为降压药剂的用途以及含有它们的药物组合物。

  公开号：

  US04435401A1
• 作为产物：
  描述：

  哌嗪 、 3-氯-6-甲氧基哒嗪 在 三乙胺 作用下， 以 二甲基亚砜 为溶剂， 反应 6.0h， 生成 3-甲氧基-6-哌嗪-1-基哒嗪
  参考文献：
  名称：

  Synthesis and evaluation of pyridazinylpiperazines as vanilloid receptor 1 antagonists

  摘要：

  A structurally biased chemical library of pyridazinylpiperazine analogs was prepared in an effort to improve the pharmaceutical and pharmacological profile of the lead compound N-(4-tertiarybutylphenyl)-4-(3-chloropyridin-2-yl)tetrahydropyrazine-1(2H)-carboxamide (BCTC). The library was evaluated for VR1 antagonist activity in capsaicin-induced (CAP) and pH 5.5-induced (pH) FLIPR assays in a human VR1-expressing HEK293 cell line. The most potent VR1 antagonists were found to have IC50 values in the range of 9-200nM with improved pharmaceutical and pharmacological profiles versus the lead BCTC. These compounds represent possible second-generation BCTC analogs. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.09.010

文献信息

• Novel (4-substituted-piperazinyl)pyridazines
  申请人：——

  公开号：EP0211457A3

  公开（公告）日：1987-07-22

  Novel (4-substituted-piperazinyl)pyridazines of formula wherein R is hydrogen, halo, C1-6alkyloxy, hydroxy or phenyl; m is the integer 2 or 3; R¹, R², R³ and R⁴ are, each independently, hydrogen, or C1-6alkyl; or where R³ and R⁴ are substituted on a different carbon atom, R³ and R⁴ taken together, may form a bivalent radical -CH₂-CH₂-; R⁵ is (aryl)C2-6alkenyl, (aryl)C2-6alkynyl, (aryl)(hydroxy)­C1-6alkyl or (aryl)(oxo)C1-6alkyl; the N-oxide forms, the pharmaceutically acceptable acid addition salts and the possible stereochemically isomeric forms, which compounds are analgesic and antitussive agents; pharmaceutical compositions containing such compounds as an active ingredient and methods of preparing said compounds and pharmaceutical compositions.

  新型(4-取代哌嗪基)吡啶嗪的化学式如下： 其中R为氢、卤素、C1-6烷氧基、羟基或苯基； m为整数2或3； R¹、R²、R³和R⁴分别独立地为氢或C1-6烷基； 或者当R³和R⁴在不同的碳原子上取代时，R³和R⁴一起可以形成二价基团-CH₂-CH₂-； R⁵为(芳基)C2-6烯基、(芳基)C2-6炔基、(芳基)(羟基)C1-6烷基或(芳基)(羰基)C1-6烷基； 这些化合物包括N-氧化物形式、药学上可接受的酸盐和可能的立体化异构体形式，这些化合物是镇痛和镇咳剂；含有这类化合物作为活性成分的药物组合物以及制备这些化合物和药物组合物的方法。
• 4-Amino-6, 7-dimethoxy-2-(4-heteroaryl-piperazino) quinazoline
  申请人：Pfizer Inc.

  公开号：US04483859A1

  公开（公告）日：1984-11-20

  2,4-Diaminoquinazoline compounds of the formula ##STR1## or a pharmaceutically acceptable salt thereof wherein R is a pyrimidinyl, pyrazinyl, pyridazinyl or triazinyl group linked to the piperazine ring by one of its carbon atoms, and optionally substituted by hydroxy, halogen, alkyl, aralkyl, alkoxy, aralkoxy,alkylthio, aryl, aryloxy and certain amino groups; their use as an antihypertensive agent and pharmaceutical compositions containing them.

  公式为 ##STR1## 的2,4-二氨基喹唑啉化合物或其药学上可接受的盐，其中R是嘧啶基、吡嗪基、吡啶嗪基或三嗪基，通过其中一个碳原子与哌嗪环相连，且可选地被羟基、卤素、烷基、芳基烷基、烷氧基、芳基氧基、烷硫基、芳基、芳基氧基和某些氨基基团取代；其作为降压剂的用途和含有它们的药物组合物。
• Antihypertensives
  申请人：Pfizer Limited

  公开号：EP0055583A1

  公开（公告）日：1982-07-07

  Antihypertensives of the formula:- or a pharmaceutically-acceptable acid-addition salt thereof, wherein "Het" is a pyrimidinyl, pyrazinyl, pyridazinyl or triazinyl group linked to the piperazine ring by one of its carbon atoms, said group being optionally substituted by one or two substituents selected from C1-C4 alkyl, C1-C4 alkoxy, hydroxy, aryl, aryloxy, C1-C4 alkyl substituted by aryl, C1-C4 alkoxy substituted by aryl, C1-C4 alkylthio, halo and -NR'R where R1 is hydrogen or C1-C4 alkyl and R2 is hydrogen, C1-C4 alkyl, C3-C7 cycloalkyl, aryl or C1-C4 alkyl substituted by aryl, or R1 and R2 taken together with the nitrogen atom to which they are attached represent a 1-pyrrolidinyl group or a 6-membered saturated heterocyclic group optionally containing a further heteroatom selected from 0, S and N, or said group "Het" is optionally substituted by a single 6,7-dimethoxy-1,2,3,4-tetrahydro- isoquinol-2-yl group.

  式中的抗高血压药 或其药学上可接受的酸加成盐，其中 "Het "为嘧啶基、吡嗪基、哒嗪基或三嗪基，通过其一个碳原子与哌嗪环相连，所述基团可任选被一个或两个取代基取代，这些取代基选自C1-C4烷基、C1-C4烷氧基、羟基、芳基、芳氧基、被芳基取代的C1-C4烷基、被芳基取代的C1-C4烷氧基、C1-C4烷硫基、卤素和-NR'R，其中R1为氢或C1-C4烷基，R2为氢、C1-C4烷基、C3-C7环烷基、芳基或被芳基取代的C1-C4烷基，或 R1和R2连同它们所连接的氮原子代表1-吡咯烷基团或任选含有选自0、S和N的另一个杂原子的6元饱和杂环基团，或所述基团 "Het "任选被一个6,7-二甲氧基-1,2,3,4-四氢-异喹啉-2-基团取代。
• S1P AND/OR ATX MODULATING AGENTS
  申请人：Biogen MA Inc.

  公开号：EP2925721B1

  公开（公告）日：2017-06-07
• US4435401A
  申请人：——

  公开号：US4435401A

  公开（公告）日：1984-03-06